GH Secretagogue Stack

This stack leverages the complementary mechanisms of three distinct peptide classes to maximise growth hormone secretion. CJC-1295 acts as a GHRH analogue, binding to GHRH receptors in the anterior pituitary and stimulating sustained growth hormone release. Its extended half-life provides a stable baseline elevation of GH levels throughout the day.

Ipamorelin functions as a selective ghrelin receptor agonist, creating sharp, pulsatile GH spikes that mimic natural circadian rhythms. Research indicates ipamorelin produces the most 'clean' GH release with minimal impact on cortisol or prolactin levels, making it ideal for long-term protocols.

GHRP-6 provides the most potent GH-releasing stimulus of the three, whilst also increasing appetite through its ghrelin-mimetic effects. Studies demonstrate that combining GHRP-6 with GHRH analogues like CJC-1295 produces synergistic effects, often doubling GH output compared to either peptide alone.

The strategic timing creates a 'wave effect': CJC-1295 maintains elevated baseline GH sensitivity, whilst the GHRPs deliver targeted pulses that align with natural sleep and recovery cycles. This approach maximises the anabolic window whilst minimising receptor desensitisation—a common issue with single-peptide protocols.

CJC-1295 (No DAC): 100-200mcg per injection, administered 2-3 times daily. Optimal timing is upon waking, pre-workout (or mid-afternoon), and before bed. Rotate injection sites between abdominal subcutaneous tissue.

Ipamorelin: 200-300mcg per injection, administered 2-3 times daily in conjunction with CJC-1295. The synergistic pairing is crucial—inject both peptides simultaneously using separate syringes at the same site.

GHRP-6: 100-200mcg per injection, typically used as a replacement for one of the daily ipamorelin doses, particularly the pre-workout injection. GHRP-6's appetite-stimulating effects make it ideal for those seeking to increase lean mass.

Injection Protocol: Use insulin syringes for subcutaneous injection. Fast for 1-2 hours before and after injections to maximise effectiveness. Our reconstitution guide provides detailed mixing instructions using bacteriostatic water.

Cycle Length: 8-12 weeks followed by a 4-week break to prevent receptor desensitisation. Advanced users may run longer cycles with periodic 1-week breaks every 6 weeks.

Sample Daily Schedule:

• 7:00 AM: CJC-1295 (150mcg) + Ipamorelin (250mcg)
• 4:00 PM: CJC-1295 (150mcg) + GHRP-6 (150mcg)
• 10:00 PM: CJC-1295 (100mcg) + Ipamorelin (200mcg)

Calculate your exact costs using our peptide cost calculator before starting.

Week 1-2: Initial adaptations include improved sleep quality and reduced sleep latency. Users typically report feeling more rested upon waking, with enhanced dream recall indicating deeper sleep phases.

Week 3-4: Recovery improvements become apparent, with reduced muscle soreness and faster between-session recovery. Skin quality often improves, with increased hydration and elasticity becoming noticeable.

Month 2: Body composition changes emerge, with users reporting modest fat loss (particularly visceral) and improved muscle definition. Energy levels throughout the day typically stabilise at higher baseline levels.

Month 3: More pronounced physique changes become apparent, including increased muscle fullness and continued fat reduction. Hair and nail growth may accelerate. Some users report improved cognitive function and mood stability.

Long-term (3+ months): Research suggests sustained protocols may support improved bone density, enhanced immune function, and better metabolic health markers. However, periodic breaks remain essential for optimal receptor sensitivity.

Common side effects include temporary water retention, particularly during the first 2-3 weeks as growth hormone levels adjust. Joint stiffness or mild discomfort may occur, typically resolving as the body adapts.

GHRP-6 specifically may cause significant appetite increases and potential hypoglycaemia if proper fasting protocols aren't followed. Some users experience fatigue 1-2 hours post-injection, which usually indicates proper GH release.

Rare but serious considerations include potential worsening of existing insulin resistance or diabetes. Individuals with active cancer should avoid GH-stimulating compounds entirely, as growth hormone may accelerate tumour growth.

Contraindications: Pregnancy, active malignancy, uncontrolled diabetes, or severe heart disease. Those with pituitary disorders should consult specialists before use.

UK researchers should review current peptide legality guidelines and ensure proper sourcing from reputable suppliers. Quality control is crucial—poor-quality peptides may contain harmful contaminants or incorrect dosing.